city Oxford covid-19 information vaccine city Oxford

Emergent expands Covid-19 vaccine manufacturing deal with AstraZeneca

Reading now: 274
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Emergent BioSolutions has entered into an agreement valued at approximately $174m for large-scale commercial production of drug substance for AstraZeneca Covid-19 vaccine candidate, AZD1222.

As part of the agreement, Emergent will offer contract development and manufacturing (CDMO) services to AstraZeneca through 2021.

This expands an $87m contract signed last month to provide development services, performance and process qualification, raw materials and for an initial capacity reservation.

AZD1222 is an adenovirus vector-based vaccine candidate co-developed by the University of Oxford and Vaccitech, while AstraZeneca obtained.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA